Categories: Wire Stories

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

The company is developing next generation lipid-based structures that kill cancer cells and expose cancer to the immune system

HANGZHOU, China–(BUSINESS WIRE)–HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.


“The ASCO meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators,” said Yuhong Xu, Ph.D., Founder and CEO of HighField. “Our lipid-based structures represent a new generation of therapeutics targeting the tumor microenvironment for a broad range of cancers.”

The abstracts reflect Phase 1 clinical trials of two kinds of lipid-based therapeutics. HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression. HER2 expressing solid tumors include breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterus and cervix cancers. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.

HFK1 Poster Presentation

Abstract ID: 3035

Title: The design, preclinical study and Phase 1 dose escalation of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.

Presenter: Dr. Yuhong Xu, Ph.D.

Presenter Date: Saturday, June 1, 2024 (9am -12pm)

HF1K16 Abstract for Publication

Abstract ID.: e14030

Title: Exploratory phase 1 study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: preliminary efficacy and mechanism as a monotherapy.

About HighField Biopharmaceuticals

HighField is a clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company also has a research and development center and a GMP-compliant production facility. HighField’s lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome containing all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumors. The company’s pipeline also includes drug encapsulated immunoliposomes for solid tumor cancers. For more information visit https://highfield.bio.

Contacts

Media Contact:

Dan Eramian

Opus Biotech Communications

danieleramian@comcast.net
425-306-8716

Business Development Contact:

Donald Wyatt

HighField Biopharmaceuticals

dwyatt@hf-biopharm.com
206-356-8196

Alex

Recent Posts

Oodles Smart Awarded Bronze Award In “Hong Kong ICT Awards 2024: Smart Living (Smart Home) Award”

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - As a leading…

8 mins ago

Oodles Smart Awarded Bronze Award In “Hong Kong ICT Awards 2024: Smart Living (Smart Home) Award”

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - As a leading…

8 mins ago

Minsuzenraku Opens First Hong Kong Location, Bringing Taiwan’s Popular No-Menu Teppanyaki Experience

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - Minsuzenraku, Taiwan's highly…

2 hours ago

New Directions East Asia 2024: Exploring the Transformative Role of Language Assessment on Education and Society

Bringing together UK and global expertise, the 12th edition of the global language testing and…

3 hours ago

Wine Connection’s Annual Wine Tasting Fair 2024: Discover Your Next Favourite

SINGAPORE - Media OutReach Newswire - 22 November 2024 - Wine enthusiasts in Singapore can…

4 hours ago

Get Wild about the Festive Season with ChristmasVille Furry Monsters Unleash Holiday Fun at Pacific Place and Starstreet Precinct

HONG KONG SAR - Media OutReach Newswire - 22 November 2024 - The spirit of…

4 hours ago